title: Stroke treatment: beyond the three-hour window and in the pregnant patient.
abstract: For acute stroke patients who arrive at the hospital within 3 h of symptom onset, the focus of care involves screening for eligibility to receive intravenous tissue plasminogen activator. The publication of the National Institute of Neurological Disorders and Stroke recombinant tissue-type plasminogen activator (tPA, or alteplase) study in 1995 (Marler, J.R. 1995, New England Journal of Medicine333: 1581-1587) spurred protocol changes, which continue to evolve, throughout the health care system in an effort to streamline the patient through the Emergency Medical System. The need to expedite patient evaluation involving emergency department, laboratory, radiology, and clinical neurology testing is clear and has been a focus of many stroke centers. For some patients, intravenous thrombolysis within 3 h has a dramatic effect on outcome. However, that is not the only course of action for acute stroke patients. This article will review some of the effective treatments for stroke patients beyond the first 3 h of their care.
authors.affiliation: Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 21224, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Cronin
authors.forename: C J
authors.initials: CJ
authors.lastname: Weisman
authors.forename: R H
authors.initials: RH
authors.lastname: Llinas
mesh_terms: D005260:Female; D006801:Humans; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator